Experience

Venatorx Pharmaceuticals, Inc.

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Associate Director CMC

  • ‏أبريل 2021 - - الحالي



Abzena

• United States
• Biotechnology Research
• 300 - 400 Employee

• Director of Process Development

  • ‏يوليو 2018 - ‏مارس 2021

  Directed the process development and cGMP manufacture of small molecule, peptide, oligonucleotide, nanoparticle and highly potent cytotoxic payloads (HPAPIs). Production of material for use in anti-body drug conjugates (ADC), pre-clinical and clinical phase studies. Directed the process development and cGMP manufacture of small molecule, peptide, oligonucleotide, nanoparticle and highly potent cytotoxic payloads (HPAPIs). Production of material for use in anti-body drug conjugates (ADC), pre-clinical and clinical phase studies.



Teva Pharmaceuticals

• Israel
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Scientist

  • ‏يوليو 2015 - ‏يوليو 2018

  Developed processes to manufacture Active Pharmaceutical Ingredients (API) in early development through Phase III clinical studies. Ensured that processes are suitable for controlling the quality of bulk API as required by cGMP, ICH and FDA regulations as well as the bulk attributes conducive to successful formulation development. Developed processes to manufacture Active Pharmaceutical Ingredients (API) in early development through Phase III clinical studies. Ensured that processes are suitable for controlling the quality of bulk API as required by cGMP, ICH and FDA regulations as well as the bulk attributes conducive to successful formulation development.



INVISTA

• United States
• Chemical Manufacturing
• 700 & Above Employee

• Process Development Chemist

  • ‏فبراير 2015 - ‏يوليو 2015



DuPont

• United States
• Manufacturing
• 700 & Above Employee

• Research Investigator

  • ‏أكتوبر 2010 - ‏أكتوبر 2014

  As a member DuPont Displays Process Development Group I designed, troubleshooted and validated synthetic operations for commercial production of organic light emitting diode (OLED) materials. Leading a team of scientists, engineers, operators, EHS and supply chain personnel I have successfully produced commercial quality OLED material on multi-kilogram scale. In addition to providing ongoing technical support to multiple contracting manufacturing organizations I successfully transferred multi-step processes to CMOs which progressed to the validation stage of commercialization using cGMP practices to ensure quality. In addition to managing the commercialization of more mature projects in the DuPont Displays Process Development Group I have used my synthetic knowledge and expertise to optimize and develop routes to new compounds. My efforts in this regard have resulted in significant cost reductions, streamlined processes and safer procedures. I have utilized numerous techniques to accomplish the above mentioned tasks including; parallel process optimization, DoE, reaction calorimetry, and solubility studies.



University of Chicago

• United States
• Higher Education
• 700 & Above Employee

• Postdoctoral Scholar

  • ‏مارس 2009 - ‏مارس 2010

  One of my most fruitful projects in the Yamamoto laboratory was the Lewis acid catalyzed Claisen rearrangement of vinyl ether-phosphonates. It was proposed that a vinyl ether-phosphonate would act as a bidentate ligand in a metal-catalyzed Claisen rearrangement resulting in increased diastereoselective and enantioselective control. I subsequently discovered that Evan’s bis(oxazoline) copper complex is an effective catalyst, capable of attaining yields and enantioselectivity of greater than 80%. One of my most fruitful projects in the Yamamoto laboratory was the Lewis acid catalyzed Claisen rearrangement of vinyl ether-phosphonates. It was proposed that a vinyl ether-phosphonate would act as a bidentate ligand in a metal-catalyzed Claisen rearrangement resulting in increased diastereoselective and enantioselective control. I subsequently discovered that Evan’s bis(oxazoline) copper complex is an effective catalyst, capable of attaining yields and enantioselectivity of greater than 80%.



Bayer

• Chemical Manufacturing
• 700 & Above Employee

• Sr. Associate Scientist I

  • ‏يناير 1999 - ‏يوليو 2003

  My contributions at Bayer Pharmaceuticals include process research and scale-up of newly discovered therapeutics for preclinical trials. My most significant contribution to the process development group was the introduction and utilization of the parallel process optimization concept. My efforts in this area led to the acquisition of a fully automated parallel process optimization platform along with DoE software. The acquisition of parallel process technology resulted in accelerated delivery of preclinical candidates.